Q&A: What's Ahead for Biosimilar Litigation and the 'Patent Dance'
Goodwin Procter partner Elaine Herrmann Blais discusses the biologics case that's expected to reach the Supreme Court and why a repeal of the Affordable Care Act could have unwelcome ripple effects.
This premium content is reserved for CC Corporate Counsel subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now